BSLN.SW
Price:
$43.6
Market Cap:
$528.48M
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus a...[Read more]
Industry
Biotechnology
IPO Date
2004-03-25
Stock Exchange
SIX
Ticker
BSLN.SW
According to Basilea Pharmaceutica AG’s latest financial reports and current stock price. The company's current PE Ratio is -622.86. This represents a change of -23252.93% compared to the average of 2.69 of the last 4 quarters.
The mean historical PE Ratio of Basilea Pharmaceutica AG over the last ten years is -15.32. The current -622.86 PE Ratio has changed 406.35% with respect to the historical average. Over the past ten years (40 quarters), BSLN.SW's PE Ratio was at its highest in in the December 2017 quarter at 179.24. The PE Ratio was at its lowest in in the December 2019 quarter at -18.04.
Average
-15.32
Median
-18.94
Minimum
-69.98
Maximum
44.72
Discovering the peaks and valleys of Basilea Pharmaceutica AG PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 194.09%
Maximum Annual PE Ratio = 44.72
Minimum Annual Increase = -163.91%
Minimum Annual PE Ratio = -69.98
Year | PE Ratio | Change |
---|---|---|
2023 | 40.50 | -9.43% |
2022 | 44.72 | -163.91% |
2021 | -69.98 | 88.53% |
2020 | -37.12 | 65.13% |
2019 | -22.48 | 58.45% |
2018 | -14.19 | -66.54% |
2017 | -42.40 | 194.09% |
2016 | -14.42 | -8.79% |
2015 | -15.81 | -28.40% |
2014 | -22.08 | -28.78% |
The current PE Ratio of Basilea Pharmaceutica AG (BSLN.SW) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
5.08
5-year avg
-8.87
10-year avg
-15.32
Basilea Pharmaceutica AG’s PE Ratio is less than Santhera Pharmaceuticals Holding AG (0.96), less than Idorsia Ltd (-0.57), less than Molecular Partners AG (-2.56), less than Evolva Holding SA (-0.31), less than Cosmo Pharmaceuticals N.V. (16.33),
Company | PE Ratio | Market cap |
---|---|---|
0.96 | $104.96M | |
-0.57 | $166.37M | |
-2.56 | $207.32M | |
-0.31 | $6.35M | |
16.33 | $1.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Basilea Pharmaceutica AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Basilea Pharmaceutica AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Basilea Pharmaceutica AG's PE Ratio?
How is the PE Ratio calculated for Basilea Pharmaceutica AG (BSLN.SW)?
What is the highest PE Ratio for Basilea Pharmaceutica AG (BSLN.SW)?
What is the 3-year average PE Ratio for Basilea Pharmaceutica AG (BSLN.SW)?
What is the 5-year average PE Ratio for Basilea Pharmaceutica AG (BSLN.SW)?
How does the current PE Ratio for Basilea Pharmaceutica AG (BSLN.SW) compare to its historical average?